Every year, infectious diseases are responsible for around 20 million deaths (source: WHO). Today, vaccination is recognized as the most effective means of prevention for protecting populations, including the most vulnerable.
Although current vaccines - administered systemically - protect against severe forms of the disease, they do not block transmission between individuals.
The need for highly effective, broad-spectrum vaccines - against all current and future strains or variants - to protect populations not only from symptomatic forms of infection, but also from transmission/contagiosity, while offering positive temperature storage logistics for equitable access, has never been clearer.
To meet this challenge, Lovaltech is developing a new generation of nasally-administered protein vaccines capable of inducing a broad-spectrum immune response at both systemic and mucosal levels ensuring optimal protection whatever the variability of the pathogen, and blocking inter-individual transmission to achieve sterilizing immunity.